Improving Donor Livers by Inhibiting TNF-α Production

Related Experiment Video

Updated: Jun 1, 2026

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation
08:39

Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation

Published on: November 7, 2020

Christopher P Zetzmann1, O Rama Swamy, George E Loss

  • 1Transplantation Research Laboratory, Ochsner Clinic Foundation, New Orleans, LA.

Ochsner Journal
|May 24, 2011
PubMed

Insights

Tissue inhibitor of metalloproteinase 3 (TIMP-3) may protect donor livers from ischemia/reperfusion (I/R) injury. This enzyme may improve liver transplant outcomes by reducing I/R damage.

Area of Science:

  • Biochemistry
  • Transplantation immunology
  • Hepatology

Background:

  • Hepatic ischemia/reperfusion (I/R) injury significantly impacts liver transplant success.
  • Understanding the biochemical pathways of I/R injury is crucial for developing protective strategies.

Purpose of the Study:

  • To explore the potential of tissue inhibitor of metalloproteinase 3 (TIMP-3) as a therapeutic agent against hepatic I/R injury.
  • To identify key enzymatic reactions in I/R injury that can be pharmacologically targeted.

Main Methods:

  • Review of biochemical pathways implicated in hepatic I/R injury.
  • Identification of TIMP-3 as a key enzyme inhibitor for potential therapeutic intervention.

Main Results:

  • TIMP-3 inhibition of specific enzymatic reactions shows promise in mitigating I/R injury.
  • Pharmacological targeting of TIMP-3 presents a potential defense mechanism against liver damage during transplantation.

Conclusions:

  • TIMP-3 is a potential therapeutic target for reducing hepatic I/R injury.
  • TIMP-3 may play a clinically significant role in improving liver transplant outcomes by protecting the donor liver from I/R damage.
Keywords:
Hepatic ischemia/reperfusionTIMP-3liver

More Related Videos

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model09:22

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model

Published on: April 2, 2017

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...